Glenmark Lifesciences Limitednow Rebranded As Alivus Lifesciencesis A Subsidiary Of Glenmark Pharmaceuticals Established In 2019Thecompany Specializes In Thedevelopment And Manufacturing Of Activepharmaceutical Ingredientsapisand Intermediateswith A Diverseportfolio Of Over 100 Apisit Serves Various Therapeutic Segmentsincluding Cardiovascularanti Diabeticand Central Nervous System Medications Alivus Lifesciences Is Committed To Innovationqualityand Sustainabilitythecompany Invests Significantly In Research And Development To Createadvanced Healthcaretherapies And Aims To Expand Its Global Presencewhileadhering To Strict Regulatory Standardsin Thefiscal Year 2022 2 It Reported A Revenueof A 1 066 Crorereflecting A Growth Of Approximately 12
Germany
